BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17051950)

  • 21. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
    Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.
    Zelefsky MJ; Lyass O; Fuks Z; Wolfe T; Burman C; Ling CC; Leibel SA
    J Clin Oncol; 1998 Oct; 16(10):3380-5. PubMed ID: 9779716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
    Zelefsky MJ; Marion C; Fuks Z; Leibel SA
    J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
    Zagars GK; Pollack A; Smith LG
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?
    Nguyen KH; Horwitz EM; Hanlon AL; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):377-83. PubMed ID: 12957248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.
    Kupelian PA; Mohan DS; Lyons J; Klein EA; Reddy CA
    Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):567-74. PubMed ID: 10701735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of dose-escalated radiotherapy in combination with long-term androgen deprivation on prostate cancer.
    Tomita N; Soga N; Ogura Y; Furusawa J; Shimizu H; Adachi S; Tanaka H; Kato D; Koide Y; Makita C; Tachibana H; Kodaira T
    Br J Radiol; 2018 Feb; 91(1083):20170431. PubMed ID: 29166142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of prostate-specific antigen kinetics after three-dimensional conformal radiotherapy with androgen deprivation therapy in patients with localized prostate cancer.
    Fukuokaya W; Kim S; Natsuyama T; Matsuzaki K; Shiomi H; Kitoh H; Utsumi N; Kurosaki H; Inoue M; Akakura K
    Int J Clin Oncol; 2018 Apr; 23(2):361-367. PubMed ID: 29151227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?
    Valicenti RK; Winter K; Cox JD; Sandler HM; Bosch W; Vijayakumar S; Michalski J; Purdy J
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):614-20. PubMed ID: 14529764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE.
    Park S; Meng MV; Elkin EP; Speight JL; DuChane J; Carroll PR
    J Urol; 2005 Nov; 174(5):1802-7. PubMed ID: 16217291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.
    Mirhadi AJ; Zhang Q; Hanks GE; Lepor H; Grignon DJ; Peters CA; Rosenthal SA; Zeitzer K; Radwan JS; Lawton C; Parliament MB; Reznik RS; Sandler HM
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):511-515. PubMed ID: 28126300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal duration of androgen deprivation in combination with radiation therapy for Japanese men with high-risk prostate cancer.
    Takaha N; Okihara K; Kamoi K; Kimura Y; Yamada T; Kawauchi A; Kobayashi K; Yamazaki H; Nishimura T; Miki T
    Urol Int; 2011; 87(1):28-34. PubMed ID: 21701133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer.
    Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
    Int J Clin Oncol; 2016 Aug; 21(4):783-790. PubMed ID: 26843024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.
    Nguyen QN; Levy LB; Lee AK; Choi SS; Frank SJ; Pugh TJ; McGuire S; Hoffman K; Kuban DA
    Cancer; 2013 Sep; 119(18):3265-71. PubMed ID: 23798338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
    Zapatero A; Mínguez R; Nieto S; Martín de Vidales C; García-Vicente F
    Eur Urol; 2009 Apr; 55(4):902-9. PubMed ID: 18485578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
    Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
    Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer.
    Zwahlen DR; Andrianopoulos N; Matheson B; Duchesne GM; Millar JL
    Brachytherapy; 2010; 9(1):27-35. PubMed ID: 19846348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.